Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer

[1]  M. Bani,et al.  BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients , 2018, Breast Cancer Research and Treatment.

[2]  M. Lux,et al.  Risk, Prediction and Prevention of Hereditary Breast Cancer – Large-Scale Genomic Studies in Times of Big and Smart Data , 2018, Geburtshilfe und Frauenheilkunde.

[3]  M. Lux,et al.  Update Breast Cancer 2018 (Part 1) – Primary Breast Cancer and Biomarkers , 2018, Geburtshilfe und Frauenheilkunde.

[4]  M. Lux,et al.  Update Breast Cancer 2018 (Part 2) – Advanced Breast Cancer, Quality of Life and Prevention , 2018, Geburtshilfe und Frauenheilkunde.

[5]  M. Lux,et al.  Update Breast Cancer 2017 – Implementation of Novel Therapies , 2017, Geburtshilfe und Frauenheilkunde.

[6]  M. Beckmann,et al.  Predicting Triple-Negative Breast Cancer Subtype Using Multiple Single Nucleotide Polymorphisms for Breast Cancer Risk and Several Variable Selection Methods , 2017, Geburtshilfe und Frauenheilkunde.

[7]  P. Fasching,et al.  Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017). , 2017, Geburtshilfe und Frauenheilkunde.

[8]  M. Beckmann,et al.  TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer , 2017, Oncotarget.

[9]  S. Hofvind,et al.  Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program , 2017, Breast Cancer Research.

[10]  L. Santoro,et al.  Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis of epidemiological studies. , 2016, Cancer treatment reviews.

[11]  Andrew H. Beck,et al.  Reproductive risk factors in relation to molecular subtypes of breast cancer: Results from the nurses' health studies , 2016, International journal of cancer.

[12]  R. Tamimi,et al.  Established breast cancer risk factors and risk of intrinsic tumor subtypes. , 2015, Biochimica et biophysica acta.

[13]  R. Schulz-Wendtland,et al.  Hormone Therapy and its Effect on the Prognosis in Breast Cancer Patients , 2015, Geburtshilfe und Frauenheilkunde.

[14]  P. Fasching,et al.  The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients , 2015, Oncotarget.

[15]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[16]  M. Lux,et al.  Association of molecular subtypes with breast cancer risk factors: a case-only analysis , 2014, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[17]  M. Rezai,et al.  Genetic Breast Cancer Susceptibility Variants and Prognosis in the Prospectively Randomized SUCCESS A Study , 2014, Geburtshilfe und Frauenheilkunde.

[18]  Christos Sotiriou,et al.  Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Lux,et al.  Polymorphisms in the RANK/RANKL Genes and Their Effect on Bone Specific Prognosis in Breast Cancer Patients , 2014, BioMed research international.

[20]  R. Schwab,et al.  Reproductive risk factors and breast cancer subtypes: a review of the literature , 2014, Breast Cancer Research and Treatment.

[21]  X. Shu,et al.  Interactions of Hormone Replacement Therapy, Body Weight, and Bilateral Oophorectomy in Breast Cancer Risk , 2014, Clinical Cancer Research.

[22]  M. Bani,et al.  Breast Cancer Risk - From Genetics to Molecular Understanding of Pathogenesis. , 2013, Geburtshilfe und Frauenheilkunde.

[23]  Patrick Neven,et al.  Genome-wide association studies identify four ER negative–specific breast cancer risk loci , 2013, Nature Genetics.

[24]  M. Lux,et al.  Association of mammographic density with hormone receptors in invasive breast cancers: Results from a case‐only study , 2012, International journal of cancer.

[25]  Jaana M. Hartikainen,et al.  The role of genetic breast cancer susceptibility variants as prognostic factors. , 2012, Human molecular genetics.

[26]  M. Lux,et al.  Association of mammographic density with the proliferation marker Ki-67 in a cohort of patients with invasive breast cancer , 2012, Breast Cancer Research and Treatment.

[27]  I. Gram,et al.  Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study , 2012, Breast Cancer Research.

[28]  M. Bani,et al.  Breast Cancer Risk - Genes, Environment and Clinics. , 2011, Geburtshilfe und Frauenheilkunde.

[29]  X. Shu,et al.  Association of hormone-related characteristics and breast cancer risk by estrogen receptor/progesterone receptor status in the shanghai breast cancer study. , 2011, American journal of epidemiology.

[30]  Alexander Cavallaro,et al.  Mammographic density as a risk factor for breast cancer in a German case–control study , 2011, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[31]  Christiana Kartsonaki,et al.  A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general population , 2010, Nature Genetics.

[32]  Lajos Pusztai,et al.  Gene-expression signatures in breast cancer. , 2009, The New England journal of medicine.

[33]  Charles M. Perou,et al.  Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.

[34]  M. Pike,et al.  American Journal of Epidemiology Original Contribution Breast Cancer Risk Factors Defined by Estrogen and Progesterone Receptor Status the Multiethnic Cohort Study , 2022 .

[35]  P. Porter,et al.  Reproductive and hormonal risk factors for postmenopausal luminal, HER‐2‐overexpressing, and triple‐negative breast cancer , 2009, Cancer.

[36]  M. Zwahlen,et al.  Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies , 2008, The Lancet.

[37]  M. García-Closas,et al.  Variation in breast cancer hormone receptor and HER2 levels by etiologic factors: A population‐based analysis , 2007, International journal of cancer.

[38]  F. Schuetz,et al.  Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy. , 2007, American journal of obstetrics and gynecology.

[39]  N. Boyd,et al.  Mammographic density and the risk and detection of breast cancer. , 2007, The New England journal of medicine.

[40]  P. Hall,et al.  Risk Factors for Hormone Receptor-Defined Breast Cancer in Postmenopausal Women , 2006, Cancer Epidemiology Biomarkers & Prevention.

[41]  K. Hornik,et al.  Unbiased Recursive Partitioning: A Conditional Inference Framework , 2006 .

[42]  R. Gelber,et al.  Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  Graham A Colditz,et al.  Risk factors for breast cancer according to estrogen and progesterone receptor status. , 2004, Journal of the National Cancer Institute.

[44]  R. Coates,et al.  Association of regimens of hormone replacement therapy to prognostic factors among women diagnosed with breast cancer aged 50-64 years. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[45]  R. Langer,et al.  Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women: The Women's Health Initiative Randomized Trial , 2003 .

[46]  J. Ranstam,et al.  Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50 302 women with breast cancer and 96 973 women without the disease , 2002, The Lancet.

[47]  J. Estève,et al.  Does a better grade of tumour occurring in women under hormone replacement therapy compensate for their lower probability of detection by screening mammography , 2002, Journal of medical screening.

[48]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[49]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[50]  R. Hoover,et al.  Estrogen replacement therapy and breast cancer survival in a large screening study. , 1999, Journal of the National Cancer Institute.

[51]  J. Cuzick,et al.  Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  A. Sasco,et al.  Impact of menopausal hormone‐replacement therapy on clinical and laboratory characteristics of breast cancer , 1998, International journal of cancer.

[53]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[54]  G. Colditz,et al.  Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer , 2011, Breast Cancer Research and Treatment.

[55]  R. Goldbohm,et al.  Breast cancer and breastfeeding: Collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease , 2002 .

[56]  K McPherson,et al.  ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. , 2000, BMJ.